secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001104659-25-052994
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA designates Organon's HADLIMA as interchangeable biosimilar to Humira across all presentations
--------------------------------------------------------------------------------

- FDA granted interchangeability for HADLIMA high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration prefilled syringe.
- HADLIMA is now interchangeable with all formulations of Humira, including low-concentration prefilled syringe and single-dose vial (granted June 2024).
- Designation based on PK, efficacy, safety, and immunogenicity study of SB5 vs Humira in moderate to severe plaque psoriasis patients.
- Interchangeability allows pharmacists to substitute HADLIMA for Humira without consulting prescriber, subject to state pharmacy laws.
- Average patient out-of-pocket cost for Humira was more than four times that of HADLIMA, per Organon data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925052994/0001104659-25-052994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925052994/tm2516205d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-052994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer